{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T10:35:36Z","timestamp":1784543736873,"version":"3.55.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s10147-025-02773-7","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T22:08:17Z","timestamp":1745878097000},"page":"1890-1895","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The role of BRCA1\/2 genetic testing in perioperative breast cancer management: advancing shared decision-making and personalized care"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-2932-7578","authenticated-orcid":false,"given":"Sayaka","family":"Obayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayu","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Nakazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misato","family":"Ogino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaaki","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Shirabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,29]]},"reference":[{"issue":"5","key":"2773_CR1","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1056\/nejmoa2005936","volume":"384","author":"C Hu","year":"2021","unstructured":"Hu C, Hart SN, Gnanaolivu R et al (2021) A population-based study of genes previously implicated in breast cancer. N Engl J Med 384(5):440\u2013451. https:\/\/doi.org\/10.1056\/nejmoa2005936","journal-title":"N Engl J Med"},{"key":"2773_CR2","doi-asserted-by":"publisher","unstructured":"Breast Cancer Risk Genes\u2014Association Analysis in More than 113,000 Women (2021). New England Journal of Medicine 384 (5):428\u2013439. https:\/\/doi.org\/10.1056\/nejmoa1913948","DOI":"10.1056\/nejmoa1913948"},{"issue":"25","key":"2773_CR3","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/nejmoa2105215","volume":"384","author":"ANJ Tutt","year":"2021","unstructured":"Tutt ANJ, Garber JE, Kaufman B et al (2021) Adjuvant olaparib for patients with BRCA1- or BRCA2- mutated breast cancer. N Engl J Med 384(25):2394\u20132405. https:\/\/doi.org\/10.1056\/nejmoa2105215","journal-title":"N Engl J Med"},{"issue":"23","key":"2773_CR4","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker KB, Hopper JL, Barnes DR et al (2017) Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317(23):2402. https:\/\/doi.org\/10.1001\/jama.2017.7112","journal-title":"JAMA"},{"issue":"3","key":"2773_CR5","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s10549-014-2890-1","volume":"144","author":"A Valachis","year":"2014","unstructured":"Valachis A, Nearchou AD, Lind P (2014) Surgical management of breast cancer in BRCA-mutation carriers: a systematic review and meta-analysis. Breast Cancer Res Treat 144(3):443\u2013455. https:\/\/doi.org\/10.1007\/s10549-014-2890-1","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"2773_CR6","doi-asserted-by":"publisher","first-page":"4706","DOI":"10.1245\/s10434-022-11756-1","volume":"29","author":"S Shubeck","year":"2022","unstructured":"Shubeck S, Sevilimedu V, Berger E et al (2022) Comparison of outcomes between BRCA pathogenic variant carriers undergoing breast-conserving surgery versus mastectomy. Ann Surg Oncol 29(8):4706\u20134713. https:\/\/doi.org\/10.1245\/s10434-022-11756-1","journal-title":"Ann Surg Oncol"},{"issue":"14","key":"2773_CR7","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.1016\/j.ejca.2013.04.028","volume":"49","author":"JL Bernstein","year":"2013","unstructured":"Bernstein JL, Thomas DC, Shore RE et al (2013) Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: A WECARE Study Report. Eur J Cancer 49(14):2979\u20132985. https:\/\/doi.org\/10.1016\/j.ejca.2013.04.028","journal-title":"Eur J Cancer"},{"issue":"18","key":"2773_CR8","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1200\/jco.20.00299","volume":"38","author":"NM Tung","year":"2020","unstructured":"Tung NM, Boughey JC, Pierce LJ et al (2020) Management of hereditary breast cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline. J Clin Oncol 38(18):2080\u20132106. https:\/\/doi.org\/10.1200\/jco.20.00299","journal-title":"J Clin Oncol"},{"issue":"5","key":"2773_CR9","doi-asserted-by":"publisher","first-page":"331","DOI":"10.6004\/jnccn.2024.0035","volume":"22","author":"WJ Gradishar","year":"2024","unstructured":"Gradishar WJ, Moran MS, Abraham J et al (2024) Breast cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Comprehensive Cancer Netw 22(5):331\u2013357. https:\/\/doi.org\/10.6004\/jnccn.2024.0035","journal-title":"J Natl Comprehensive Cancer Netw"},{"issue":"2","key":"2773_CR10","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","volume":"35","author":"S Loibl","year":"2024","unstructured":"Loibl S, Andr\u00e9 F, Bachelot T et al (2024) Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 35(2):159\u2013182. https:\/\/doi.org\/10.1016\/j.annonc.2023.11.016","journal-title":"Ann Oncol"},{"key":"2773_CR11","unstructured":"Japanese Breast Cancer Society (2022) Epidemiology and Diagnosis, vol 2. Guidelines for breast cancer treatment \/ Japanese Breast Cancer Society ed. Kanehara Publishing Co."},{"key":"2773_CR12","unstructured":"Japan Hereditary Breast and Ovarian Cancer Comprehensive Treatment System Organization (2024) Hereditary Breast and Ovarian Cancer (HBOC) Clinical Practice Guidelines. Kanehara Publishing Co."},{"key":"2773_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-021-02194-2","author":"Z Jia","year":"2021","unstructured":"Jia Z, Li J, Zhang Y et al (2021) Contralateral risk-reducing local therapy in breast cancer patients with BRCA1\/2 mutations: systemic review and meta-analysis. Cancer Cell Int. https:\/\/doi.org\/10.1186\/s12935-021-02194-2","journal-title":"Cancer Cell Int"},{"issue":"3","key":"2773_CR14","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1002\/ijc.29032","volume":"136","author":"BAM Heemskerk-Gerritsen","year":"2015","unstructured":"Heemskerk-Gerritsen BAM, Rookus MA, Aalfs CM et al (2015) Improved overall survival after contralateral risk-reducing mastectomy in BRCA1\/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis. Int J Cancer 136(3):668\u2013677. https:\/\/doi.org\/10.1002\/ijc.29032","journal-title":"Int J Cancer"},{"issue":"1","key":"2773_CR15","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s10549-013-2583-1","volume":"140","author":"DGR Evans","year":"2013","unstructured":"Evans DGR, Ingham SL, Baildam A et al (2013) Contralateral mastectomy improves survival in women with BRCA1\/2-associated breast cancer. Breast Cancer Res Treat 140(1):135\u2013142. https:\/\/doi.org\/10.1007\/s10549-013-2583-1","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"2773_CR16","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1007\/s00266-021-02506-x","volume":"46","author":"K Stanek","year":"2022","unstructured":"Stanek K, Zimovjanova M, Suk P et al (2022) Bilateral prophylactic nipple-sparing mastectomy: analysis of the risk-reducing effect in BRCA1\/2 mutation carriers. Aesthetic Plast Surg 46(2):706\u2013711. https:\/\/doi.org\/10.1007\/s00266-021-02506-x","journal-title":"Aesthetic Plast Surg"},{"issue":"10","key":"2773_CR17","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1200\/jco.2014.56.8626","volume":"33","author":"CC Riedl","year":"2015","unstructured":"Riedl CC, Luft N, Bernhart C et al (2015) Triple-modality screening trial for familial breast cancer underlines the importance of magnetic resonance imaging and questions the role of mammography and ultrasound regardless of patient mutation status, age, and breast density. J Clin Oncol 33(10):1128\u20131135. https:\/\/doi.org\/10.1200\/jco.2014.56.8626","journal-title":"J Clin Oncol"},{"issue":"5","key":"2773_CR18","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1007\/s12282-019-00955-6","volume":"26","author":"W Murakami","year":"2019","unstructured":"Murakami W, Tozaki M, Nakamura S et al (2019) The clinical impact of MRI screening for BRCA mutation carriers: the first report in Japan. Breast Cancer 26(5):552\u2013561. https:\/\/doi.org\/10.1007\/s12282-019-00955-6","journal-title":"Breast Cancer"},{"issue":"12","key":"2773_CR19","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/j.annonc.2022.09.159","volume":"33","author":"CE Geyer","year":"2022","unstructured":"Geyer CE, Garber JE, Gelber RD et al (2022) Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1\/2 and high-risk, early breast cancer. Ann Oncol 33(12):1250\u20131268. https:\/\/doi.org\/10.1016\/j.annonc.2022.09.159","journal-title":"Ann Oncol"},{"key":"2773_CR20","unstructured":"Japanese Breast Cancer Society (2022) Treatment, vol 1. Guidelines for breast cancer treatment\/Japanese Breast Cancer Society ed. Kanehara Publishing Co."}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02773-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-025-02773-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02773-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T07:38:20Z","timestamp":1758872300000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-025-02773-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,29]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["2773"],"URL":"https:\/\/doi.org\/10.1007\/s10147-025-02773-7","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,29]]},"assertion":[{"value":"1 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There was no conflict of interest in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Institutional review board was waived due to the nature of this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}